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“There are two ways to be fooled.   
One is to believe what isn’t true,  
the other is to refuse to accept what is true” 
Søren Kirekegaard, Danish philosopher (1813-1855)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To Patrik, Petter and Axel 
  
  
  
ABSTRACT 
Background: Venous thromboembolism (VTE) contributes to a large health burden and 
incidence increases exponentially with age. ~25% patients will experience a recurrent event 
and there is a 2-fold risk for death in the following years. Risk prediction remains a challenge. 
Aims to: Investigate a presumed overlap between cardiovascular disease and VTE. Expand 
current knowledge of established pathways in VTE risk by combining clinical and genetic 
epidemiology. Apply affinity proteomics to identify novel plasma susceptibility biomarkers. 
Methods and results: 39 single nucleotide polymorphisms (SNPs) associated with coronary 
artery disease (CAD) and 18 risk VTE-SNPs from candidate gene approach studies or 
genome-wide association studies (GWAS) were identified from a literature search. The SNPs 
were genotyped in 2,835 women from the ThromboEmbolism Hormone study (TEHS), a 
Swedish nationwide case-control study in women (2002-2009). Association was assessed 
with logistic regression. Clinical and genetic predictors that contributed significantly to the fit 
of the logistic regression model were included in the prediction models. The genetic 
predictors that contributed to first VTE were assessed in a cohort of 1010 women with VTE 
from TEHS, followed up until a recurrence, death or November 2011 (TEHS follow-up).  
The SNP r579459 in the ABO locus was the only CAD-SNP that was significant associated 
with VTE (OR 1.57 (95% CI: 1.39-1.78, p= 6.4 10-13)). Seven VTE risk-SNPs (F5 rs6025, 
F2 rs1799963, ABO rs514659, FGG rs2066865, F11 rs2289252, PROC rs1799810 and 
KNG1 rs710446) with 4 SNP-SNP interactions contributed to the genetic risk score for VTE 
with an AUC of 0.66 (95% CI: 0.64-0.68). After adding clinical risk factors the AUC attained 
0.84 (95% CI: 0.82-0.85). The goodness of fit of the genetic and combined scores improved 
when significant SNP-SNP interaction terms were included.  In TEHS follow-up study, the 
overall recurrence rate was 20 per 1000 person-years (95% CI; 16-24). Carriers of the risk 
alleles of F5 rs6025 (FVL) (HR=1.7 (95% CI; 1.1-2.6)) and F11 rs2289252 (HR=1.8 (95% 
CI; 1.1-3.0)) had significantly higher rates of recurrence compared to non-carriers. The 
cumulative recurrence was 2.5-fold larger in carriers of both F5 rs6025 and F11 rs2289252 
than in non-carriers at 5 years follow-up. 
Plasma samples from 88 VTE cases and 85 controls, part of the Venous thromboembolism 
Biomarker Study (VEBIOS), were screened against 408 candidate proteins targeted by 755 
antibodies using multiplex bead arrays. Proteins that significantly associated with VTE after 
Bonferroni correction were tested for replication in plasma samples of 580 cases and 589 
controls from the FARIVE study. In VEBIOS, plasma levels of four proteins, HIVEP1, 
VWF, GPX3 and PDGFB were significantly associated with VTE after Bonferroni 
correction. VWF and PDGFB successfully replicated in FARIVE with increased plasma 
levels in VTE cases compared to controls as initially observed in VEBIOS. 
Conclusion: ABO locus was the only shared genetic risk factor between CVD and VTE. A 
limited set of genetic predictors improved prediction of incident VTE in women at high risk. 
Our data indicated that interactions among SNPs increase the goodness of fit when predicting 
VTE. A combination of genotypes i.e. F11 rs2289252 and FVL, may be of potential clinical 
relevance for risk prediction for recurrence. Affinity plasma proteomics proved to be a 
valuable research strategy to discover novel biomarkers.  
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 INTRODUCTION 
Venous thromboembolism (VTE) comprises of deep vein thrombosis (DVT) and pulmonary 
embolism (PE) and is the third most common cardiovascular disease (CVD) after myocardial 
infarction and stroke. Even if VTE is responsible for a large global public health burden, the 
public awareness is strikingly low for this potentially fatal but preventable disease (1-3). 
About 160 years ago in Berlin, Rudolf Virchow set the stage for modern ideas for VTE. He 
found evidence that blood clots (thrombi) form in the veins and could move from their site 
(emboli) to the lungs. He proposed three principal causes of clot formation; injury to the 
vessel wall, impaired blood flow (stasis) and hypercoagulability. This concept, known as the 
Virchow’s triad still holds today (4).  
Several milestones have been reached in understanding of the complex interactions between 
genetic, environmental and acquired risk factors for this disease (5). New effective 
anticoagulant treatments have been introduced during the first decade of the 21st century, 
though still with an increased risk of bleeding complications as drawback (6).  
The development of high throughput technologies for profiling of protein composition in 
plasma allows for exploration of the proteome in plasma samples of large cohorts and the 
discovery of new tentative biomarkers for VTE (7). Risk prediction remains a challenge for 
both first VTE and recurrence, thus identification of biomarkers specific for VTE could open 
up for new possibilities in clinical management as well as provide leads to explore the 
pathophysiology of VTE (8). 
The focus of this thesis is on the application of genetic and proteomic approaches in an 
attempt to gain a further understanding of the complexity of VTE to potentially contribute to 
improved risk prediction.  
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 BACKGROUND 
2.1 EPIDEMIOLOGY 
Venous thromboembolism (VTE) has an incidence of 1-2/1000 person years that 
exponentially increases with age and is higher among Caucasians compared to Blacks and 
Asians (2, 9, 10). Around 25% of the patients will suffer from a recurrent VTE within 5 years 
after discontinuation of anticoagulant treatment with the highest recurrence rate in the first 
half year after diagnosis and in the younger population with unprovoked VTE (9, 11, 12). 
Around 10 to 20 per cent will face an impaired quality of life after a first DVT because of 
post thrombotic syndrome in the lower limbs that leads to chronic swollenness and ulceration 
(2). In a Norwegian population cohort the case-fatality rate was 13% within the first year 
from diagnosis (10), and in the follow-up of the Dutch ‘Multiple Environmental and Genetic 
Assessment of Risk Factors for Venous Thrombosis study’ (MEGA) an overall shorter life 
expectancy with 5 years and a two-fold increased risk for death up to 8 years was reported 
(13).  
2.2 ETIOLOGY 
VTE is multifactorial disease with interacting genetic, acquired and environmental risk 
factors (14). According to Lijfering et al. description in the Figure 1, all individuals hold a 
risk to develop a VTE, a ‘thrombosis potential’ that increases with age. Whether an 
individual reaches the ‘thrombosis threshold’ (diagnosed with VTE) is decided by several 
interacting factors (15). An individual’s ‘thrombosis potential’ is influenced of more 
persistent risk factors over time i.e. genetic and acquired risk factors (Figure 1). The latter 
defined as obesity, malignancy, rheumatic systemic disorders and other chronic conditions. 
Environmental risk factors are often regarded as transient factors but crucial in causing an 
individual to reach above the ‘thrombosis threshold’ (Figure 1). Among the environmental 
risk factors are surgery, immobilisation (i.e. cast or orthosis, hospitalisation), long distance 
flight, pregnancy and the exposure to oestrogens from combined contraceptives and hormonal 
replacement therapy. Even if the environmental risk factors have a large contribution to risk, 
no such provoking factors can be identified in one third of the patients diagnosed with 
incident VTE (5, 15).  
An example of how risk factors may interact is through the casual pathways of activated 
protein C (APC)-resistance. High body mass index (BMI) leads to Factor VIII (FVIII)-related 
increased APC-resistance and hypercoagulability, an effect that is amplified in carriers of  
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Factor V Leiden (FVL) and ABO blood group non-O (16).  These interacting factors 
influence the ‘thrombosis potential’ in an individual (Figure 1)  
 
 
2.2.1 Heritability 
In both case-control studies and nation-wide family studies, VTE has been observed to cluster 
in families (17-20), suggesting that there is an important underlying genetic component. 
Family and twin studies of thrombophilia have estimated the heritability for VTE to be 
approximately 60 % (21-23). However, from the French genome wide association study 
(GWAS) on unrelated individuals, Germain et al reported that common genetic variants 
explain about 35% of the genetic variance underlying VTE susceptibility, whereas only ~5% 
could be attributed to established VTE loci (24). 
2.2.1.1 Family history of VTE 
Family history of VTE is a well-established risk factor for incident VTE, where the risk is 
more pronounced in families where more than one relative have been affected with VTE and 
if the thrombosis was unprovoked and/or occurred at a younger age (25, 26).  Family history 
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Figure 1 shows the thrombosis potential of an individual with factor V Leiden and of an individual 
with blood group non-O. Both experience a short period of immobilization at a similar age. This leads 
to an excess of the thrombosis threshold level in the individual with factor V Leiden which 
consequently leads to deep vein thrombosis, while the individual with blood group non-O does not 
develop thrombosis. Br J Haematol. 2010;149:824-33. Figure is reused with the kind permission from 
W.M. Lijfering
Thrombosis threshold Deep vein thrombosis
Immobilisation
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of VTE was only modestly associated with recurrence according Zöller et al. in the Swedish 
Multigeneration Study (27).  
2.2.1.2 Genetic risk factors 
Known strong genetic factors for VTE include deficiency of inhibitors in the coagulation 
system; Antithrombin, Protein C and its co-factor Protein S (28-30). These risk factors are 
very rare in the population, but highly penetrant in some families with a diversity of different 
mutations described (14). Among those with moderate risk, the polymorphisms in 
coagulation Factor V, FVL (~4 fold risk) and the prothrombin (F2 G20210A) (~2 fold risk) 
are common in the Caucasian population, ~7-10% and ~3-5%, respectively (Figure 2) (14, 
15, 31, 32). FVL cause an impaired activated Protein C inhibition of thrombin generation, i.e. 
APC resistance (31). G20210A increases synthesis of Prothrombin, and thereby also 
thrombin generation (32). Carriership of the genetic variant for ABO blood group non-O is 
not a part of inherited thrombophilia screening in clinical practice. Still it is a very common 
(~40%) and well-established genetic risk factor for VTE (~1.5-2 fold risk), explained largely 
by higher levels of Factor VIII (FVIII) and von Willebrand factor (VWF) (Figure 2) (33-35). 
According to Heit et al. the risk genotypes for FVL, F2 G20210A and ABO blood group 
non-O, contribute to ~40% risk of the incident VTE (35). 
In clinical practice, current tests for inherited thrombophilia after first VTE do not reduce the 
incidence of recurrent events (36, 37). This is also reflected by the fact that in three different 
prediction scores for recurrence, HER DOO2 (HER for women; hyperpigmentation, oedema, 
or redness; and DOO2; D dimer, Obesity, Old age and 2 is too (also) continue anticoagulant 
treatment), Vienna Prediction model and DASH (D dimer, Age, Sex (male) and Hormonal 
therapy) neither FVL or the G20210A polymorphism in Prothrombin gene alone, nor 
inherited thrombophilia, are important predictors (38-40).  
Through GWAS, new susceptibility genetic variants/loci have emerged for VTE (Figure 2). 
These are described as single nucleotide polymorphisms (SNPs) and are common in the 
general population (minor allele frequency larger than 1 %). The corresponding risk estimates 
are relative low (less than 1.5 fold) compared to previous detected genetic variants (Figure 2) 
(41). Most of these new variants are associated with intermediate traits for VTE, i.e. STXBP 
is associated with VWF level and KNG1 is associated with activated partial thromboplastin 
time and Factor XI (FXI) level (42, 43).  However, a recent meta-analysis with ~66,000 
individuals by Germain et al. has identified two new risk VTE-loci; TSPAN15 and SLC44A2, 
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for which the functional link to thrombosis formation is still not established (44). It remains 
an open question how to best translate this new genetic information into clinical practice. 
With the exception from van Hylckama Vlieg et al.’s recent publication, there are few studies 
on the association between common genetic variants and recurrent event of VTE (45). 
 
 
Figure 2: Historical perspectives of known genetic risk factors for VTE. J Thromb Haemost. 
2011; 11 Suppl. 1:111-2. Figure reused with the kind permission from P.E Morange. 
 
2.2.2 Gender 
The incidence for VTE is reported to be higher in women during child-bearing age attributed 
to pregnancy and the influence of oestrogen containing contraceptives. However, when 
female specific risk factors are taken into account, the risk is twofold higher for incident VTE 
in men compared to women in all age groups and pronounced in the youngest group (46). 
This also holds for recurrent VTE, making it plausible that there is a sex-specific difference in 
genetic risk (9, 12, 47). 
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2.2.3 Cardiovascular disease and VTE 
There is an increased risk of CVD amongst patients previously diagnosed with VTE 
suggesting that VTE is a predictor of subsequent arterial thrombosis (13, 48, 49). In a 
Norwegian population cohort, the Tromsø study, 64% of arterial thrombotic events among 
the VTE patients were attributable to the incident VTE (49). However, the relationship 
between VTE and subsequent CVD is more likely to be explained by common etiological 
factors than to be causal according to more recent study (50). Increasing age and obesity are 
the only cardiovascular risk factors with robust influences on VTE risk in prospective 
population studies, whereas for smoking, hyperlipidaemia, hypertension and diabetes mellitus 
the observed associations are inconsistent (51-53). Furthermore, arterial and venous 
thrombosis share common mechanisms i.e. activation of blood coagulation (54-56), 
hypofibrinolysis (57, 58) and inflammation (59). 
2.3 IDENTIFICATION OF PLASMA BIOMARKERS  
2.3.1 Definition of a biomarker 
According to the National Institutes of Health Biomarkers Definitions Working group from 
1998, a biomarker is defined as; ‘A characteristics that is objectively measured and evaluated 
as an indicator of normal biological process, pathological process, or pharmacological 
response to a therapeutic intervention’(60). 
Biomarkers are usefully categorised depending on intended use to; a) diagnostic, which 
incorporates detection of disease, b) prognostic, that predict the course of a disease (i.e. 
recurrence, progression and survival) and c) predictive, that allows for prediction of the 
response of a treatment (7, 60).  
2.3.2 Plasma biomarkers in clinical practice for VTE management  
2.3.2.1 D-dimer 
The only plasma biomarker for VTE that is in clinical use for diagnosis or risk prediction is 
D-dimer, a split product from the cross-linked fibrin clot. Elevated D-dimer is observed in 
increased thrombin generation as a result of hypercoagulability and associated with both first 
and recurrent VTE (61). In Well’s diagnostic score, D-dimer has a high negative prediction 
value to rule out diagnosis for those with low suspicion of acute thrombosis (62). However, 
D-dimer has very low specificity and furthermore it is increased in many other conditions 
apart from VTE, i.e. cancer, pregnancy, inflammation and older age. A biomarker with high 
positive predictive value for VTE, equivalent to troponin for acute myocardial injury, i.e. 
myocardial infarction, is still missing.  
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Risk scores to predict recurrence of VTE that incorporate D-dimer level together with clinical 
data have been proposed (38-40). Still, these models does not satisfactory discriminate those 
who will have a recurrent VTE from those who will not. Furthermore, the value of a negative 
D-dimer test, sampled one month after stopped anticoagulant treatment of an unprovoked 
VTE, as an indicator of a low recurrence risk has been challenged (63, 64). A recent cohort 
study reported that even if a D-dimer test was negative twice (during anticoagulant treatment 
and one month after stopped treatment), the risk for recurrence was not low enough in men to 
discontinue anticoagulant treatment according to clinical practice (64).  
2.3.2.2 Factor VIII 
High FVIII levels in plasma is a well-established risk factor for first VTE (65). For 
recurrence, FVIII levels have currently been found to have a dose-dependent association with 
risk in the large MEGA follow-up study (66). Subjects within the highest category of FVIII 
levels (> 200 IU/dL) had a threefold risk for recurrence of VTE compared to those in the 
lowest range (</= 100 IU/dL). The performance of the risk prediction score for recurrence 
DASH (D-dimer level, Age, Sex and Hormone use), improved with FVIII, even when D-
dimer was left out from the score (DASH AUC=0.64 and ‘FASH’ AUC=0.67, respectively) 
(40, 66). It remains to be further evaluated if FVIII level can be implemented in clinical 
practice.  
There is a need to improve both the precision and the discrimination power in the prediction 
scores for recurrence to better identify high risk individuals in whom the benefits of long-
term anticoagulant treatment overrule the yearly risk of serious bleeding associated with this 
treatment (8, 67). 
2.3.3 Technology platforms for Biomarker Discovery studies  
The main high throughput technologies for discovery of putative plasma biomarkers are 
based on mass spectrometric analysis (MS) and affinity proteomics. For affinity proteomics 
there are different platforms for planar arrays or bead arrays that can be used for multiplexed 
protein profiling in plasma (68). These arrays are built with single-capture antibodies (single 
binders), sandwich immunoassays (dual binders) or antigen- or peptide-capture arrays (69, 
70).  
2.3.3.1 ‘Shotgun’ (untargeted) Mass spectrometry 
Shotgun mass spectrometry is based on the conversion of intact proteins in a sample into 
peptide fragments. These peptides are identified by their mass-to charge (m/z ratio), and 
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thereafter the protein is identified by studying a database of peptides. Experiments involve 
the comparison of results from two small groups of samples with identification of many 
intensity peaks that represent peptide levels differences (69, 71). The method has the potential 
to detect up to 5,000 different proteins, but with limitations in the number of samples that can 
be analysed in parallel, and thereby a high false discovery is expected (71). Extensive sample 
preparation is frequently necessary i.e. protein depletion or purification of samples. Many 
proteins are labile, and degradation during sample preparation or storage can impair proper 
protein identification (7, 69, 71).  
2.3.3.2 Affinity Proteomics based on suspension bead arrays 
Affinity Proteomics with suspension bead arrays has successfully been used to identify 
biomarkers in various diseases, i.e. gastrointestinal cancer, osteoporosis and amyotrophic 
lateral sclerosis (68, 72, 73). These suspension bead arrays are built with single binders such 
as antibodies from the Human Proteome Atlas (HPA) (74). According to the latest release of 
the Atlas (version 13), 24,000 polyclonal antibodies are available corresponding to 17,000 
protein-coding genes in human (74, 75).  With this multiplexed technology platform, it is 
possible to generate protein profiles of 384 protein targets per array in 384 samples in 
parallel. This method has the advantage of not involving any sample purification, 
fractionation or depletion steps (68, 76, 77). However, there is a vast dynamic range of 
concentration of different proteins in plasma, why single binder arrays are vulnerable to 
potential off-target interactions, requiring further verification of identified tentative targets 
(77). Targeted MS is an important tool to further confirm candidate proteins and holds also 
the potential for quantification with dual binder assays (ELISA) (78, 79). 
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 AIMS 
 
The main objectives of this thesis were to: 
 Expand current knowledge of established pathways of importance in VTE risk by 
combining clinical and genetic epidemiology 
 Apply affinity proteomics to identify novel susceptibility plasma biomarkers that 
may improve prediction tools for VTE-risk and provide new leads to further 
understand mechanisms contributing to the pathogenesis of VTE 
More specifically, the three first papers focused on investigating the genetics of VTE in 
Swedish young and middle-age women with the aim to: 
 Investigate a presumed overlap between CVD and VTE 
 Evaluate the contribution of potentially important predictors in a combined genetic 
and clinical risk score for first VTE  
 Explore if important genetic predictors for first VTE also were associated with 
recurrence  
The fourth paper was a proteomic biomarker discovery study aiming to identify novel 
plasma biomarkers for VTE risk. 
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 MATERIAL AND METHODS 
4.1 STUDIES 
4.1.1 The ThromboEmbolism Hormone Study (TEHS) 
TEHS is a nation-wide case-control study of VTE in women initiated by the Medical 
Products Agency (MPA) and conducted through the Centre for Pharmacoepidemiology at 
Karolinska Institutet. TEHS, previously well described by Bergendal et al (80), was 
designed to investigate how environmental and genetic factors affect the risk of VTE, with 
a focus on women taking different combined hormonal contraceptives or menopausal 
hormone therapy. A total of 1,433 cases and 1,402 controls, aged between 18 and 65, were 
recruited between 2003 and 2009. Cases included both out- and in-patients recruited from 
43 hospitals in Sweden, who had a first-time episode of DVT in lower limbs and/or PE. All 
cases of VTE were objectively confirmed with established diagnostic imaging methods. 
Exclusion criteria were previous VTE, current or recent (< 5 years) malignancy and 
pregnancy. Female controls were selected randomly from the population register held by 
the National Board of Taxation and matched to birth year of the cases. Information was 
obtained through telephone interviews, precluding participation of non-Swedish-speaking 
women. All participants donated 5 mL of whole blood and the DNA was prepared using 
QIAGEN FlexiGene DNA kit.  
4.1.2 TEHS follow-up study 
TEHS follow-up study is a prospective cohort study on recurrent event from the cases in 
TEHS. The follow-up study aims to identify important risk factors for a recurrent event in 
young and middle aged women, previously described in detail by Ljungqvist et al (81). 
Briefly, in 2011, all cases included in TEHS who were still living in Sweden were followed 
up by a questionnaire. Information about recurrent events was obtained from the 
questionnaire and from data recorded in the Swedish Patient Register (82). All events in the 
register and/or stated in the questionnaires were verified by a review of medical records. 
The recurrent event had to be diagnosed by an objective radiological method and regarded 
by the treating physician as an indication for resuming anticoagulant treatment for at least 
three months. From the Swedish Cause of Death Register, data was obtained for the causes 
of death of deceased participants in TEHS (83). 
4.1.3 Venous thromboembolism biomarker study (VEBIOS) 
VEBIOS was initiated in 2010 at Centre for Hematology, Karolinska University Hospital in 
collaboration with Karolinska Institutet and Science for Life Laboratory, KTH Royal Institute 
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of Technology, Stockholm with the aim of identifying and translating biomarkers for VTE 
using resources available through the HPA (74). VEBIOS, in detailed described in Paper IV, 
is an on-going case-control study since January 2011 and conducted by the Coagulation Unit 
at Karolinska University Hospital with recruitment of cases from three regional hospitals. 
Eligible cases are patients from 18 to 70 years of age with first VTE, which have been 
referred from the Emergency clinics after diagnosis for a follow up at the respective 
outpatient clinics for Thrombosis and Haemostasis. Cases have been treated with 
anticoagulants during six to twelve months with any type of anticoagulant medication. Cases 
are identified by the physicians at the out clinics at respective hospital. Patients found with 
severe thrombophilia are not eligible. Controls are matched to cases for age and gender and 
continuously recruited from the population living in Stockholm County, based on a 
randomised selection using the Swedish Tax Agency register (84). Exclusion criteria for 
participants were personal history of VTE, pregnancy during the last three months before the 
index date or an active cancer within the last five years. Blood sampling is performed at the 
Coagulation unit by a research nurse and from each participant both plasma and whole blood 
are stored in a biobank. Plasma samples have been centrifuged at 2000g for 15 minutes at 
room temperature and aliquots were snap frozen and stored at −80 °C. The cases have been 
sampled one to six months after discontinuation of anticoagulant.  
4.1.4 FARIVE 
The FARIVE study was used in Paper IV as a replication study to VEBIOS and is a French 
multicentre case-control study carried out between 2003-2009 with the aim to study the 
interaction of environmental, genetic and biologic risk factors for first VTE and risk of 
recurrence. The study has previously been well described and involves consecutive inpatients 
or outpatients from 18 years of age, confirmed by diagnostic imaging and treated for a first 
episode of DVT and/or PE (85). The controls were age- and sex matched and consisted of in- 
and outpatients, free of personal history of venous and arterial thrombotic disease. Exclusion 
criteria for all eligible participants were diagnosis of cancer, short life expectancy owing to 
other causes, renal - or liver failure. The replication study was based on a subset from 
FARIVE (86). 
4.2 ETHICS PERMISSION 
Informed written consent was obtained from all participants in accordance with the 
Declaration of Helsinki. The TEHS, TEHS follow-up study, VEBIOS and FARIVE were 
approved by the regional research ethics committees (KI 01-255), (KI 2010/1200-31/1), (KI 
2010/636-31/4) and (Paris Broussais-HEGP 2002-034), respectively. 
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4.3 CLINICAL VARIABLES 
Clinical data was obtained from TEHS, TEHS follow up study (Paper I-III) and FARIVE 
(Paper IV) (80, 81, 85).  Clinical variables are described in detail in the respective publication 
and manuscript (80, 81, 85). The clinical variables used from TEHS in Paper I-III included 
localisation of thrombosis (PE and DVT), and self-reported information from questionnaires. 
This included weight, height, BMI, cardiovascular risk factors, immobilisation and hormonal 
use during the 3-month period preceding diagnosis for cases and index date for controls and 
family history of VTE.  
In VEBIOS the information was obtained from a questionnaire asked to be filled in by all 
participants covering information about established risk factors for VTE and CVD and in 
detailed described in Paper IV. The biometry, i.e. lengths, weight and BMI was measured by 
the research nurse the day of blood sampling.  
4.4 GENOTYPING 
Genotyping was performed by using the Illumina GoldenGate platform, read and called by 
using the Illumina BeadXpress and Illumina GenomeStudio 2011.1 software at the 
SNP&SEQ Technology Platform, Uppsala, Sweden. SNPs in F5 (rs6025), F13A1 (rs5985), 
and F2 (rs1799963) were genotyped by Pyrosequencing™ technology (ISO standard 2004) at 
the Royal Institute of Technology, Stockholm, Sweden (87). Complementary genotyping was 
done with Taqman® SNP genotyping assays (Applied Biosystems, CA, USA) and analysed 
using StepOne software v2.1. Standard quality control procedures were performed with SNP 
exclusion due to call rate (<95%) and/or deviation from Hardy-Weinberg equilibrium 
(p<0.005). Subjects with a low call rate (<90%) were excluded. Genotyping was performed 
on plates containing cases and controls and was completed in one stage each for the Illumina 
and Taqman® platforms. 
4.5 AFFINITY PROTEOMICS 
4.5.1 Antibody reagents 
Antibodies to the selected protein targets were obtained from the polyclonal antibody 
reagents resource generated by HPA (74). The HPA produces polyclonal antibodies towards 
recombinantly expressed human protein targets based on in-silico selection of antigen 
regions, so called protein epitope signature tags (PrEST), which consist of the most unique 
50-150 amino acid regions of each protein as compared to all other human proteins (70). The 
antibody reagents selected for the plasma profiling in paper IV were checked according to 
following quality criteria; (a) concentration higher than 0.05 mg/mL and (b) clear indication 
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of the specific binding to the candidate target protein or protein fragment. The latter was 
based on confirmation of antibody binding by planar arrays with PrEST fragments, 
determination of antibody specificity with western blot and finally immunohistochemical or 
immunofluorescence stained tissue arrays that had been annotated by trained pathologists 
(74). 
4.5.2 Methodology 
4.5.2.1 Suspension Bead Array Generation 
Protein plasma profiles were generated using suspension bead arrays in which HPA 
antibodies were coupled to color-coded magnetic beads as illustrated in Figure 3 and 
previously described (68, 77).  The coupling efficiency of each antibody to its corresponding 
bead ID was confirmed by the incubation with a labelled anti-rabbit antibody and represented 
as a median of fluorescence intensity (MFI).  Equal amounts of each bead ID were combined 
to generate the 384 antibody-plex suspension bead array (68, 76, 77). 
4.5.2.2 Sample preparation 
Thawed plasma samples were transferred to microtiter plates in a final format of 384 well 
plate, randomized according to pre-set criteria in which matching of cases and controls as 
well as confounders as age, gender and centre were taking in account. The samples in the 
well plates were then labeled with biotin and after dilution heat-treated for 30 minutes at 56 
°C (68, 76, 77). 
4.5.2.3 Protein Profiling 
The suspension bead array was dispensed into a 384 well plate and the samples were added 
for overnight incubation, allowing for antibodies binding to the targeted proteins in plasma. 
After washing a detection solution of R-Phycoerythrin-labeled streptavidin (SAPE) was 
added and incubated for 30 minutes. SAPE enables the captured proteins to be measured in 
parallel as a relative level of immunocapture reactions on beads by fluorescence in MFI using 
assay laser detection FelxMap3D instrument (Luminex) (Figure 3) (68, 76, 77).   
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Figure 3: Methodological overview of Affinity plasma proteomics using suspension bead 
array 
4.6 STATISTICAL METHODS 
In the univariate analysis for genetic variants and VTE-risk in Paper I-II, unconditional 
logistic regression was applied to calculate the odds ratio (OR) with 95% confidence interval 
(95% CI) assuming an additive genetic model with adjustment to age. Significance level was 
set to p-value < 0.05. Bonferroni correction was used in Paper I to correct for multiple testing. 
The predictive models in Paper II were based on logistic regression. For the clinical model all 
the variables were statistically significant at the 0.05-level and kept in the model. The genetic 
variables were removed one at a time, according to a backward stepwise selection process, 
using a p-value of 0.05 as cut-off limit for inclusion. The sum of the regression coefficients 
was used as a risk score to calculate the area under the receiver-operating characteristics 
(ROC) curve (AUC). The prediction model was calibrated and cross-validated to assess over-
fitting and over-optimism. Goodness of fit of the combined model was assessed by inspecting 
the observed proportion of cases by classes of risk and the Hosmer-Lemeshow was 
performed to test for lack of fit of the combined model. The AUC is known to be insensitive 
to differences between prediction models therefore clinical risk reclassification table was 
calculated to compare the performance between different scores (88). 
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Recurrence rate in Paper III was calculated as the number of events over the accumulated 
patient time. Cox-proportional hazard model was used to evaluate risk between groups and 
hazard ratio (HR) with 95% CI were reported. Crude HR’s were assessed in univariate 
analysis assuming a dominant model for the genetic variables. Cumulative recurrence was 
calculated with the Kaplan-Meier estimator by subgroups and tested for differences with the 
log-rank test.  
In Paper IV, linear regression was applied to test the association of proteomic data and VTE, 
estimating the mean difference for the targeted protein levels in plasma with the adjustment 
for age, gender and additionally by centre in FARIVE. Log-transformation was applied to 
remove any skewness in the proteomic data distribution. Significance level was set to p-value 
< 0.05, Bonferroni-corrected. 
In Paper I, the univariate analysis was estimated by PLINK and the ABO-locus’ haplotype 
analysis was carried out using THESIAS software (89, 90). In Paper II-III, all analyses were 
performed in Stata version 13. In Paper IV, the analyses were performed using the R 
statistical computing software (91). 
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 RESULTS AND DISCUSSION 
5.1 PAPER I 
In the first paper, we studied the presumed overlap between arterial CVD and VTE by 
exploring if common genetic variants associated with CVD-risk were also found associated 
with VTE.  
We identified from a literature search 39 SNPs in 32 loci associated with CAD from 
GWAS. These were genotyped in TEHS along with genotyping for ABO-blood group and 
common genetic variants for VTE. The association of SNPs with VTE was assessed by 
logistic regression.  
5.1.1 Results 
Only rs579459 in the ABO locus demonstrated a significant association with VTE (OR 1.57 
(95% CI: 1.39-1.78, p-value 6.4 x 10-13)). Interestingly, rs579459 was found to be in 
perfect linkage disequilibrium (LD) with a SNP in ABO intron 1 (rs2519093) that had 
previously been reported independently associated with VTE from ABO blood group 
genotype. Our haplotype analysis of the ABO SNPs revealed s579459 to be a perfect proxy 
for ABO blood group subtype A1 (Table 1). A tentative association between ANRIL and 
VTE in the discovery analysis in TEHS failed to replicate in a meta-analysis of 4 
independent cohorts (total n=7181).  
Table 1: Haplotype analysis of the ABO-locus in chromosome 9q34 
ABO A1 vs B O1 vs O1v/O2 A1 vs A2 O vs non-O intron 1 Frequency 
Haplotype rs8176749 rs512770 rs8176704 rs514659 rs579459 contr. cases 
O1 C G G A T 0.43 0.35 
A1 C G G C C 0.22 0.30 
A2 C G A C T 0.09 0.07 
O1v/O2 C A G A C 0.01 0.01 
O1v/O2 C A G A T 0.16 0.14 
B T G G C T 0.09 0.11 
Where the effect allele is marked in bold and contr. is controls 
 
ABO All O & A2 vs. A1 & B  
Haplotype OR [95% CI] p-value OR [95% CI] p-value 
O1 Reference  reference   
A1 1,69 [1,46 - 1,94] 5 10-13 1,66 [1,45 - 1,89] 3 10-14 
A2 1,03 [0,84 - 1,27] 0,76 1  
O1v/O2 1,32 [0,81 - 2,14] 0,27 1  
O1v/O2 1,03 [0,87 - 1,21] 0,73 1  
B 1,57 [1,30 - 1,90] 4 10-6 1,54 [1,28 - 1,85]  4 10-6 
Where the OR is odds ratio and [95% CI] is 95% confidence interval 
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5.1.2 Discussion  
There is methodological aspects that may have influenced our results. The common CAD 
risk SNPs that emerged from GWAS have all weak effect estimates (<1.5). Although TEHS 
was composed of ~2,800 women, the power was insufficient for a discovery analysis where 
significance of association was corrected for multiple testing.  
In our statistical association test we adjusted for variables which were not true confounders 
defined to be associated with the exposure (genetic variants) and affect the outcome (VTE) 
well illustrated in direct acyclic graphs (DAG) (Figure 4 and 5) (92). This introduced 
residual confounding and gave an incorrect picture of plausible association of VTE which 
in our study was ANRIL. The importance to use confounders stringently has to be stressed 
in genetic studies, as most genetic and clinical variables could impossible be associated 
with the genetic variants as an exposure (15).  
 
 
Figure 4. Direct acyclic graphs (DAG) with examples of confounders for VTE. COC is 
combined contraceptives with oestrogens 
 
 
Figure 5. DAGs illustrating that genetic and clinical variables are not associated with the 
exposure ANRIL and therefore no confounders 
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outcome
VTE
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A genetic variable may act as an effect modifier in the causal pathway, i.e. carriers for FVL 
have much higher risk for VTE compared to non-carrier if they are exposed to combined 
oral contraceptive with oestrogens, OR 20.6 compared to OR 3.4, well demonstrated by 
Bergendal et al. in TEHS (93).  
However, it has to be stressed there that are some situations when a genetic variable may be 
a true confounder (Figure 4). This was the case for ABO blood group non-O tagging SNP 
(rs514659) that was used as confounder. The association with ABO rs579459 in intron 1 
and VTE declined from an OR of 1.57 to 1.24 when rs514659 was introduced as 
confounder in the association analysis. This led us to further question if the genetic variant 
in ABO intron 1 really was independent from ABO blood group genotype as previously 
suggested by Heit el al (35, 94). We found that haplotype LD plots may not be sufficient to 
claim a genetic variant’s independent association with a disease. When we constructed 
haplotypes from four ABO blood group tagging SNPs (O1, A1, A2, B, O1v/O2) and 
rs579459, we found that ABO rs579459 in intron 1 was a prefect proxy for ABO blood 
group haplotype A1 (Table 1).  
Apart from the ABO locus, we did not find support for other genetic risk factors shared 
between CVD and VTE in Swedish women. ABO blood group has repetitively been found 
associated with both CVD and VTE. This is to a large extent explained by that levels of 
FVIII and VWF varies between blood groups (34, 95, 96).  
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5.2 PAPER II 
In the second paper we evaluated a genetic risk score, in isolation and when combined with 
clinical risk factors.  
From a literature search, 18 VTE-risk SNPs were identified from candidate gene approach 
studies or GWAS, and genotyped in DNA samples from 2,835 women from TEHS. Clinical 
and genetic (SNPs) predictors that contributed significantly to the fit of the logistic regression 
model were included in the prediction models. Risk scores were evaluated by calculating the 
AUC.  
5.2.1 Results 
All clinical risk predictors were significant with the highest risk estimate for immobilisation. 
In the genetic risk prediction model, 7 SNPs, F5 rs6025 (FVL), F2 rs1799963 (F2 
(G20210A), ABO rs514659, FGG rs2066865, F11 rs2289252, PROC rs1799810 and KNG1 
rs710446, contributed significantly to the risk for VTE and remained in the model. 
Interactions were found between ABO rs514659 and F5 rs6025 and between ABO rs514659 
and F11 rs2289252. Furthermore, we found a significant interaction between one or two 
alleles of KNG1 rs710446 and F5 rs6025. There were no major differences in risk estimates 
in the combined model except for family risk of VTE, where the risk estimate declined 
slightly (Table 2). The clinical risk score attained an AUC of 0.80 (95% CI: 0.79-0.83) and 
the genetic risk score reached an AUC of 0.66 (95% CI: 0.64-0.68). The combined score 
attained an AUC of 0.84 (95% CI: 0.82-0.85) with a significant improvement of risk 
prediction over the clinical risk score (p-value < 0.001) (Figure 6). For comparison, we 
investigated how the genetic risk score by de Haan et al. based on 5 SNPs performed in 
TEHS (97). This score attained an AUC of 0.65 (95% CI: 0.63-0.67) compared with the AUC 
of 0.69 attained in the de Haan et al. study. The AUC for the TEHS genetic risk score was 
significantly larger (p-value=0.03) than de Haan et al.’s. The AUC is known to be insensitive 
subtle to differences between prediction models and therefore we proceeded to calculate 
clinical risk reclassification tables. In the high-risk group (70-100% risk), 51 of 815 were 
wrongly assigned to a lower than observed risk category using de Haan et al.’s score 
combined with TEHS clinical predictors, while the TEHS combined score classified all high-
risk individuals correctly. If only FVL rs6025 and F2 1799963 were used in the combined 
risk score, 80/815 participants were misclassified in the high-risk group (70-100%). The 
clinical risk score misclassified 174/815 in the high risk group. 
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Table 2: Association and significance from the clinical, genetic and combined prediction 
models in TEHS including SNP-SNP interactions 
Variable Clinical Genetic Combined 
Clinical:       
Height (cm) 1.04***  1.04*** 
BMI (kg/m2) 1.11***  1.12*** 
Immobilization† 16.5***  18.9*** 
Long distance flight† 1.6***  1.6*** 
Hormonal use†‡ 4.3***  4.1*** 
Family history of VTE 2.4***  2.0*** 
Genetic:    
F5 rs6025  6.8*** 7.7*** 
F2 rs1799963  1.94** 1.74* 
ABO rs514659  1.70*** 1.67** 
F11 rs2289252  1.37*** 1.29* 
PROC rs1799810  1.14* 1.10 
KNG1 rs710446  1.56** 1.50* 
FGG rs2066865  1.37*** 1.43*** 
SNP interaction:    
F5 rs6025_rs6025  0.39** 0.36** 
F5 rs6025_ ABO rs514659  1.63* 1.65* 
ABO rs514659_F11 rs2289252  0.82* 0.85 
KNG1 rs710446_rs710446  0.84* 0.86 
Where: * p-value < 0.05; ** p-value < 0.01; *** p-value < 001, BMI, body mass 
index; †, within three month from diagnosis or index date; ‡, oestrogen containing 
contraceptive and menopausal replacement therapy(oral or patch)  
 
 
Figure 6:  ROC curves for the clinical (solid line), genetic (dashed) and combined (dotted) 
model in TEHS. Clinical risk score, AUC 0.80 (0.79-0.82); Genetic risk score, AUC 0.66 
(0.64-0.68) and Combined score, AUC 0.84 (0.82-0.86) 
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5.2.2 Discussion 
It is recommended to first evaluate existing prediction models before suggesting a new one 
(98). In TEHS, we evaluated the previously published genetic risk score from de Haan et al. 
with 5 SNPs used as a single predictor with very similar performance in AUC compared to 
TEHS own genetic risk score. However, it is well known that the AUC is insensitive for 
differences in prediction models (88, 99). We continued by comparing TEHS clinical-genetic 
combined model with TEHS clinical models combined with de Haan’s 5 SNPs or FVL and 
F2 (G20210A) (today in clinical use). The clinical risk reclassification tables clearly 
demonstrated the difference and the risk for misclassification to a lower than observed risk 
category depending of what prediction models that are used (On-line table 4 of the paper II). 
In TEHS, we found that a limited set of genetic predictors including SNP-SNP interactions 
improved prediction for VTE independently from family history of VTE. This is in contrast 
to family history of VTE that has been suggested to be more useful in risk assessment (17). 
To continue, family history of VTE has previously been reported in TEHS, compatible with 
Bezmer et al. and Suchon et al., with low positive predictive value with the established 
clinical genetic risk factors used in thrombophilia screening (17, 100, 101). This has a clinical 
implication, as there is today no recommendation for thrombophilia screening in anticipation 
of risk exposure in individuals with no personal history of VTE or known thrombophilia 
defect in the family. For instance, as many as 50 percent of the cases in TEHS who had 
undergone surgery did receive thrombosis prophylaxis with low-molecular heparin but still 
developed VTE (102), indicating the need to improve current risk assessment practice, i.e. to 
identify those individuals in whom increased doses or longer duration of thrombosis 
prophylaxis treatment is warranted. 
It can be argued that the need of risk prediction models is of less importance in women 
compared to men, as women have half the risk for VTE when female specific risk factors are 
taken into account (46). However the use of combined contraceptives with oestrogens are 
common among young and middle aged women (in TEHS 33% of the women under 50 years 
of the cases) and increases the risk for VTE on average 5-fold (93). Even if the incidence is 
overall low in younger age (1 per 10,000 person years) it is the underlying risk in 
combination with transient provoking factors for each individual (thrombosis potential) that 
decide if this individual will suffer from VTE (reach thrombosis threshold), well-illustrated 
by Lijfering et al (Figure 1) (10, 15). We find that our combined risk score may have a 
clinical implication in women, i.e. prior to high-risk situations or decision on the 
recommendation of the use of combined contraceptives, but needs to be further evaluated in 
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other cohorts and improved. It has to be noted that TEHS does not include pregnant women 
thus our prediction score cannot be applied for this condition without modification. However, 
a prediction score for thrombosis prophylaxis during pregnancy is already clinically 
implemented in Sweden (103, 104). 
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5.3 PAPER III 
The objective in the third paper was to explore if the genetic predictors for first event VTE in 
TEHS were also associated with the risk of recurrence.  
In TEHS follow up study, 1,010 women with first VTE were available for analysis of the 
recurrence rate with respect to the seven genetic predictors identified in paper II; F5 rs6025 
(FVL), F2 rs1799963 (G20210A), ABO rs514659 (non-O ABO blood group), FGG 
rs2066865, F11 rs2289252, PROC rs1799810 and KNG1 rs710446.  
5.3.1 Results 
During a mean period of 5 years, there were 101 recurrent VTE with an estimated rate of 20 
per 1,000 person-years (95% CI: 16-24). The recurrence rate was highest in women with an 
unprovoked first event and obesity. Carrier of the risk alleles of F5 rs6025 (FVL, HR 1.7 
(95% CI: 1.1-2.6)) and F11 rs2289252 (HR 1.8 (95% CI: 1.1-3.0)), had a significant higher 
recurrence rate compared to non-carriers of the risk allele. The cumulative recurrence was 
2.5-fold larger in carriers of both F5 rs6025 and F11 rs2289252 (14.6% (95% CI: 9.9-21.3%)) 
than in non-carriers (5.9% (95% CI: 3.4-10.3%)) at 5 years follow-up (Figure 7). In 
subgroups analysis among women with first unprovoked VTE, the cumulative recurrence was 
even larger in carriers for both risk alleles compared to the non-carriers (21.9% (95% CI: 
13.7-34.0%) versus 7.5% (95% CI: 3.4%-16.0%)) (Figure 8). The log rank tests demonstrated 
the statistical differences between the Kaplan Meier curves in both analysis.  
We followed up the predictive ability of the 7 SNPs of our own genetic risk score from Paper 
II by comparing women grouped into three groups according to the number of SNPs for 
which they carried the risk allele(s): 0-2, 3-4, and 5-7 SNPs. The cumulative recurrence 5 
years into the study was 12.8% for carriers of 5-7 SNPs compared to 8.9% for carriers of 3-4 
SNPs and 4.6% for the group carrying the risk allele(s) of 0-2 SNPs. There was not 
statistically significant difference between the three groups. 
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Figure 7: Cumulative recurrence comparing carriers of both risk alleles versus non-carriers 
for F5 rs6025 and F11 rs228925 
 
 
Figure 8: Subgroup analysis of the women with unprovoked fist VTE; cumulative recurrence 
comparing carriers of both risk alleles versus non-carriers for F5 rs6025 and F11 rs2289252 
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5.3.2 Discussion 
For clinicians, prediction of VTE recurrence remains a challenge. Even if risk prediction 
models, i.e. HER DOO2, Vienna Prediction Model and DASH, have been suggested, the lack 
of precision gives the models limited power to identify high risk individuals who would 
benefit for extended treatment with anticoagulants (38-40). Furthermore, the models include 
few clinical variables together with D-dimer levels, and screening for thrombophilia was not 
shown to add any predictive value (38-40).  
The TEHS follow up study had few recurrent events over the follow-up period of 5 years 
compared to other studies which most probably could be explained by the study design of 
TEHS that comprised young and middle age women with both provoked and unprovoked 
first VTE (81). This left us with a reduced power to analyse whether the genetic markers 
(SNPs) which predicted first VTE in TEHS (Paper II) also were associated with recurrence. 
In our association test we therefore chose to use a dominant model instead of the more 
commonly used additive model for the SNPs (carrier=1 non-carrier=0 of a risk allele in a 
SNP). We expected only a minor influence on the results as the risk for recurrence is 
relatively small on the log scale for a carrier compared to a non-carriers of a risk allele.  
Our finding that F11 rs2289252 was associated on recurrence is interesting as there is 
growing evidence that FXI is a key player in the pathogenesis of thrombosis (105-109). It has 
also gained attention as an anticoagulant drug target (110, 111). The F11 rs2289252 
association with first time VTE has partly been explained by increased levels of FXI (112, 
113). In the MEGA follow-up study, an association with recurrence was also reported for F11 
but with two other SNPs; rs2036914 and rs3822057. However, these two SNPs were not 
independently associated with VTE  (LD r2 = 0.91 in the 1,000 Genomes study) (114).  We 
continued to follow up the finding of F11 rs2036914 from MEGA follow up in relation to 
rs2289252. In the 1,000 Genomes study the LD was only r2=0.46 between the SNPs (114). 
However, Germain et al. has clearly demonstrated an at-risk haplotype, derived from these 
two SNPs, with as high frequency as ~0.40 that increased the risk with an OR of 1.40 (24). 
We observed that 5 years into the follow up study in TEHS, women who carried risk alleles 
for both F11 rs2289252 and F5 rs6025 had a slightly higher cumulative recurrence compared 
to those who carried risk alleles for ≥5 of the 7 SNPs which predicted first VTE in TEHS. 
Based on this, we believe there is a risk of misclassification of individuals at high risk to a 
lower risk-group if a sum of alleles/genetic variants is applied in a prediction model. 
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Much research remains to be conducted regarding risk prediction of reoccurrence of VTE. 
Analyses in collaboration between research groups would provide more statistical power to 
find the optimal set of genetic markers to integrate with clinical predictors and plasma 
biomarkers.  
In the genetic risk scores for first VTE, F11 rs2036914 was included in de Haan et al.’s 5 
SNPs score whereas F11 rs2289252 was added in TEHS own score (Paper II) (97). It is 
tempting to believe that the haplotype of F11 rs2289252 and rs2036914 would be more 
useful in risk assessment of both incident VTE and recurrence than to use of only one of these 
SNPs in F11 (24).  
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5.4 PAPER IV 
Our aim in the fourth paper was to apply a plasma proteomics approach for the discovery of 
novel biomarkers for VTE that could improve current prediction tools and to identify new 
leads to explore the pathophysiology involved in VTE.  
In the discovery experiment, plasma samples of 88 cases and 85 controls from participants of 
VEBIOS were screened for 408 proteins targeted by 755 HPA antibodies using multiplex 
bead arrays. The selection of targets was based on a) evidence on association with VTE or 
intermediate traits and b) HPA antibodies’ availability and predefined quality criteria. 
Proteins that significantly associated with VTE after Bonferroni correction were tested for 
replication in citrated plasma samples of 580 cases and 589 controls from FARIVE.  
5.4.1 Results 
In VEBIOS, plasma levels of four proteins, Human Immuno-deficiency Virus type I 
Enhancer binding Protein 1 (HIVEP1), VWF, Glutathione Peroxidase 3  (GPX3) and 
Platelet-derived growth factor beta (PDGFB) targeted by HPA050724, HPA002082, 
HPA059686 and HPA011972 antibodies, respectively, were found significantly associated 
with VTE after Bonferroni correction, with a good concordance between measurements in 
citrate and EDTA plasma. Even though the direction of associations of GPX3 and HIVEP1 
with VTE observed in FARIVE paralleled those observed in VEBIOS, they did not reach 
statistical significance. Furthermore, in FARIVE a trend for a genotype-specific (HIVEP1 
rs169713) association was found between HIVEP1 protein levels and VTE risk. VWF 
(Figure 9) and PDGFB (Figure 10) successfully replicated in FARIVE with significantly 
higher signals in plasma from VTE cases compared to controls. These two potential 
biomarkers were modestly correlated ( ~0.30) with each other and in a joint model 
independently associated with VTE risk (FARIVE; p < 0.001 and p = 0.002 for VWF and 
PDGFB, respectively). 
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Figure 9: Boxplot of VWF (targeted by HPA002082) in VEBIOS and FARIVE where X-axis 
is disease status and Y-axis is normalized median fluorescent intensity 
 
 
 
Figure 10: Boxplot of PDGFB (HPA011972) in VEBIOS and FARIVE where X-axis is 
disease status and Y-axis is normalized median fluorescent intensity 
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5.4.2 Discussion 
We identified one novel candidate biomarker, PDGFB, for VTE risk. The significant 
difference in VWF levels between VTE patients and controls, served as a proof of principle 
for our study design and methodological approach.  
The study included plasma sample sets from a discovery study - VEBIOS and an independent 
replication study - FARIVE. Both studies have the advantage of being well phenotyped and 
they are similar in study design with the exception of recruitment of controls. Most 
importantly the protocols for collection, handling and storage of blood samples applied were 
comparable, however the sampling time from diagnosis differ for the cases; in VEBIOS it 
was one month after stopped treatment (at least 7 months from diagnosis) and in FARIVE it 
was during the acute phase (within the first weeks from diagnosis) under influence of 
anticoagulant treatment. This introduces selection bias that has to be taken into account when 
interpreting the results. With the knowledge that proteomics analysis is multidimensional and 
prone to many technical and methodological pitfalls, adopting a stringent statistical approach 
was necessary. 
PDGFB is a protein expressed in the endothelium. The increased plasma levels could reflect 
increased protein synthesis and secretion in VTE patients compared to controls, or could 
reflect tissue leakage under endothelial dysfunction. The association was independent of 
sampling time from diagnosis and of anticoagulant treatment. However, at this point we do 
not know if PDGFB could be causal to VTE or reactive (a consequence of the disease) 
(Figure 11) (115). To further elucidate PDGFBs role as a biomarker, both functional and 
clinical studies (preferable in prospective cohorts) are required. 
Our most significant finding in the discovery phase was increased levels of HIVEP1 in VTE 
patients compared to controls. This finding was not replicated in FARIVE although a 
tendency of higher levels was found for the patients with VTE compared to controls. In 
addition, a trend in FARIVE for an association between HIVEP1 plasma levels and VT risk 
was observed, dependent on the VTE-associated rs169713 polymorphism previously 
identified from GWAS (116). The biological function of HIVEP1 is unknown which is why 
we cannot rule out at this stage that sampling time or anticoagulant treatment may have 
affected the protein levels in the VTE patients in FARIVE (Figure 11). Our preliminary 
results observed for HIVEP1 require further validation in additional materials with both DNA 
and plasma samples but suggests that findings from GWAS studies can be translated into 
proteomics studies. 
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Figure 11. Pathways showing influences of genetic (G) and environmental (E) factors on 
chronic diseases. A) Model of causal and reactive pathways due to effects of G and E on gene 
expression (R), as reported by Schadt et al. (Schadt et al. 2005). B) Model of causal and 
reactive pathways from (A) extended to include the proteome (P) and metabolome (M). 
Biomarkers 2012, 17, 483-489. Copyright © 2012 Informa UK, Ltd. Figure reused with the 
kind permission from. S.M Rappaport. 
 
Furthermore, our putative biomarker has to survive many steps before application in clinics. 
Work has begun to verify the identified protein. Even if we could replicate PDGFB in an 
independent sample set, verification is necessary because single binder assays are vulnerable 
to off-target binding of other proteins in plasma (77). Initially we are using targeted MS with 
immunoprecipitation. In parallel, dual binders enzyme-linked immunosorbent assay (ELISA) 
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is developed to enable quantification of the protein in plasma (78, 79). This enables 
validation of PDGFB with estimation of the sensitivity and specificity for disease status. 
However, PDGFB’s predictive value is dependent on the prevalence of VTE in the cohort 
PDGFB will be applied on. Only a biomarker (or a panel of biomarkers) with high positive 
predictive value (PPV) or negative predictive value (NPV) will finally be considered for 
prediction in clinical practice (7, 60, 117, 118). 
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 CONCLUSION 
Conclusions from the genetic studies in TEHS in Paper I-III: 
 Apart from the ABO locus, a presumed overlap in genetic risk between arterial CVD 
and VTE could not be established when studying common genetics variants of CAD 
and the association on VTE risk. 
 A limited set of genetic predictors improved prediction of VTE in women at high 
risk, independently of family history of VTE. Our data indicate that interactions 
among SNPs increase the goodness of fit when predicting VTE.  
 For the first time, F11 rs2289252 was found to be associated with risk of recurrent 
VTE in women. A combination of genotypes of F11 rs2289252 and FVL SNPs may 
be of potential clinical relevance for risk prediction. 
Conclusions from the proteomic study in VEBIOS and FRAIVE in Paper IV: 
 The platelet-derived growth factor beta (PDGFB)  was identified as a candidate 
biomarker for VTE-risk. 
 Affinity plasma proteomics proved to be a valuable research strategy to discover 
novel biomarkers and opened new promising perspectives for VTE and its clinical 
outcomes. 
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 FUTURE PERSPECTIVES 
We are in the ‘omics’ era with powerful high throughput methods. During the last 10 years 
a dozen susceptibility genetic markers have been generated in the field of VTE, however 
with insufficient predictive value as single markers (119). To incorporate genetic markers 
in prediction scores for both incident VTE and recurrence have been suggested (97, 120). 
However, I am convinced that we have not used the full potential of the information that 
genetic markers can provide us with in combination with clinical predictors and plasma 
biomarkers. This demands more advanced models that allow for biological interaction and 
synergetic effects to be incorporated to increase accuracy and discrimination power. For 
clinical application any prediction models have to be user friendly and the panel of SNPs 
available as routine detection assays at a reasonable cost from a health economic 
perspective.  
In terms of plasma proteomics, I am cautiously optimistic. The discovery of tentative 
biomarkers for VTE reflects the interplay between genetic and environmental factors 
(Figure 11) (115). However, to take a biomarker from discovery to clinical application is a 
major task, requiring access to large patient cohorts and the expertise of epidemiologists, 
biostatisticians, bioinformaticians, engineers, basic scientists and clinicians in the VTE 
field. 
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